

























































Synthesis of Stable NAD+ Mimics as Inhibitors for the
Legionella pneumophila Phosphoribosyl Ubiquitylating
Enzyme SdeC
Jerre M. Madern,[a] Robbert Q. Kim,[b] Mohit Misra,[c, e] Ivan Dikic,[c, e] Yong Zhang,[d] Huib Ovaa
+,[b] Jeroen D. C. Codée,[a] Dmitri V. Filippov,*[a] and Gerbrand J. van der Heden van Noort*[b]
Stable NAD+ analogues carrying single atom substitutions in
either the furanose ring or the nicotinamide part have proven
their value as inhibitors for NAD+-consuming enzymes. To
investigate the potential of such compounds to inhibit the
adenosine diphosphate ribosyl (ADPr) transferase activity of the
Legionella SdeC enzyme, we prepared three NAD+ analogues,
namely carbanicotinamide adenosine dinucleotide (c-NAD+),
thionicotinamide adenosine dinucleotide (S-NAD+) and benza-
mide adenosine dinucleotide (BAD). We optimized the chemical
synthesis of thionicotinamide riboside and for the first time
used an enzymatic approach to convert all three ribosides into
the corresponding NAD+ mimics. We thus expanded the known
scope of substrates for the NRK1/NMNAT1 enzyme combination
by turning all three modified ribosides into NAD+ analogues in
a scalable manner. We then compared the three NAD+ mimics
side-by-side in a single assay for enzyme inhibition on Legion-
ella effector enzyme SdeC. The class of SidE enzymes to which
SdeC belongs was recently identified to be important in
bacterial virulence, and we found SdeC to be inhibited by S-
NAD+ and BAD with IC50 values of 28 and 39 μM, respectively.
Introduction
Many cellular proteins are decorated with post-translational
modifications (PTMs) during their life-time that control their
function, cellular localization and activity. One of these PTMs is
adenosine-diphosphate-ribosylation (ADP-ribosylation), in
which a monoadenosine diphosphate ribosyl transferase en-
zyme (mART) transfers an ADPr fragment from an NAD+
molecule to the nucleophilic side chain of an amino acid
residue of a target protein, releasing nicotinamide in the
process. This mono ADPr-modification can be elongated in a
linear or branched fashion, giving rise to linear poly- and
branched poly-ADPr chains. Enzymes generating both the
mono-ADPr and poly-ADPr modification play crucial roles in
distinct biological processes.[1] Another essential PTM that
regulates many key cellular processes is ubiquitylation, in which
a small 8.5 kDa protein called ubiquitin (Ub) is attached to the
target protein.[2] Installment of Ub is regulated by a cascade of
three enzymes known as E1-activing enzyme, E2-conjugating
enzyme and E3-ligase. In this ATP-dependent process the
combination of specific E1-E2-E3 enzymes dictates the choice of
substrate and site of ubiquitylation. Prokaryotes do not contain
the Ub system, but a variety of bacterial pathogens do have the
capability to use or hijack the host’s Ub system.[3] Recently, it
was discovered that the Legionella pneumophila bacterium uses
a family of so-called SidE effector enzymes to mediate the ADP-
ribosylation of Ub as a crucial first step in ubiquitylating host
proteins of their own choice, finally leading to Legionnaires
disease in immunocompromised individuals. These SidE effec-
tors contain multiple domains with different catalytic activities,
including a mART and a phosphodiesterase (PDE) domain.
Initially, the mART domain catalyzes the transfer of ADPr to
arginine 42 (R42) of Ub, releasing nicotinamide. Subsequently
the PDE domain will activate the phosphodiester bond,
facilitating the covalent attachment to a serine residue of a host
substrate protein while displacing adenosine mono-phosphate
(AMP; Figure 1).[4–8] In this way, the enzyme is able to
ubiquitylate the substrate, via a unique phosphoribosyl (Pr)
linkage without the need for either E1-E2-E3 enzymes or ATP.
Recent studies link this phenomenon of Pr ubiquitylation to the
development and maintenance of a vacuole in which Legionella
replicates, by modifying host proteins involved in ER fragmenta-
tion and membrane recruitment.[9,10] The unusual Pr ubiquityla-
tion, with ADPribosylation of Ub as first step, is an interesting
target for drug development, since this pathway seems to be
Legionella specific as it has not been identified in mammals so
far. Knocking down the SidE effectors severely effects bacterial
virulence and hence these proteins are bona-fide drug
targets.[11]
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There are two distinct classes of ART enzymes, referred to as
diphtheria-toxin-like or cholera-toxin-like, which have a HYE or
RSE catalytic triad, respectively.[12] Both types transfer ADPr in a
reaction that proceeds through a transition state having a
ribosyl oxocarbenium ion character (Figure 2A). Several NAD+
mimics that are unable to form such an oxocarbenium
intermediate, such as carbanicotinamide adenosine dinucleo-
tide (c-NAD+, 1), thionicotinamide adenosine dinucleotide (S-
NAD+, 2) and benzamide adenosine dinucleotide (BAD, 3;
Figure 2B), have been developed as inhibitors of NAD+
consuming enzymes and have shown moderate to good
inhibition.[13–15] c-NAD+ has been shown to inhibit activity of the
cholera toxin A ART enzyme[16] and NAD+-consuming enzymes
Sirt3/5,[17] but was ineffective towards NAD+-glycohydrolase. c-
NAD+ is also ineffective in inhibiting PARP1, while BAD is a low
micromolar PARP1 inhibitor.[18] S-NAD+ was developed more
recently and shows inhibition of NAD+-dependent enzyme
CD38.[19]
In this light, we decided to explore these three promising
NAD+ analogues, c-NAD+ (1), S-NAD+ (2) and BAD (3), for their
inhibitory potential on the ART function of the Legionella SidE
family member SdeC. Fully synthetic approaches towards BAD
and c-NAD+ have been reported, but formation of the
dinucleotide, through coupling of adenosine monophosphate
and the phosphorylated ribose analogues remains troublesome.
Therefore we decided to adopt a chemo-enzymatic procedure,
recently used to prepare S-NAD+, to form the difficult
pyrophosphate linkages in c-NAD+ and BAD.[19] We synthesized
the carbanicotinamide riboside and benzamide riboside using
optimized procedures from literature and developed a novel
synthesis for the thioriboside. Subsequent chemo-enzymatic
conversion using nicotinate riboside kinase (NRK1) to produce
the nicotinamide mononucleotides (NMNs) and subsequent
action of nicotinamide mononucleotide adenylyl transferase
Figure 1. Schematic representation of mART and PDE action of SidE-family enzymes on ubiquitin.
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(NMNAT1) would yield us the three NAD analogues c-NAD+ (1),
S-NAD+ (2) and BAD (3).
The known carbanicotinamide riboside (4)[17] and benzamide
riboside (6;[14,20] Scheme 1B) were prepared following the
optimized reported procedures. We devised a new synthetic
route for the third analogue, thionicotinamide riboside (S-NR, 5)
that was recently described.[19] We opted to employ the
synthesis depicted in Scheme 1A that is based on our prior
studies on thioribosides.[21] First, we synthesized protected
thioribitol 13 from ribose, essentially as described by us and
others.[21,22] In brief, the synthesis started with readily accessible
and inexpensive D-ribose that was first converted into lactol 9,
the aldehyde functionality of which was next reduced to give
ribitol 10. Mesylation and double bromide substitution then
provided dibromide 12, which was treated with sodium sulfide
to give thioribitol 13. After removal of the three p-meth-
oxybenzyl ethers by acidolysis, we selectively protected the
primary alcohol with a TBDPS group and the secondary alcohols
with acetyls to obtain 16. The thioether was then oxidized to a
sulfoxide using m-CPBA at low temperature and with controlled
amounts of the oxidizing agent to avoid an overoxidation to
the corresponding sulfone. The subsequent Pummerer-rear-
rangement was performed by dissolving the sulfoxide obtained
from 16 in acetic anhydride and heating the reaction mixture to
120 °C. The rearrangement proceeded regio- and stereoselec-
tively to provide thioribosyl donor 18 as a mixture of anomers.
We observed that the Pummerer rearrangement of a per-O-
acetylated thioribitol led to the formation of 4-O-acetyl
thioribitol by oxidation at C-4, and hence the electron donating
properties of the silyl protection at C5 was essential in our
synthesis. Donor 18 was next glycosylated with nicotinamide in
a Vorbrüggen-type glycosylation, using TMSOTf in acetonitrile,
yielding a mixture of α/β-anomers in 75% yield. Finally, the silyl
ether was removed using HF in pyridine, and the acetyls were
removed using ammonia in methanol at 0 °C, at which stage
the anomers could be separated by RP-HPLC to provide
thionicotinamide riboside 5. Thus, S-NR 5 was obtained in 16
steps in an overall yield of 3.6%, which compares favorably
with the method previously reported for the synthesis of this
compound.[19] With nicotinamides 4 and 5 and benzamide 6 in
hand, we next focused on the enzymatic phosphorylation of
the 5’-hydroxy function using NRK1, followed by introduction of
the pyrophosphate using NMNAT1 (Scheme 1B). The riboside
was dissolved in buffer containing ATP, MgCl2 and DTT after
which NRK1 was added to install the phosphate group on the
5’-hydroxy function selectively. After one hour, complete
formation of the nicotinamide mononucleotides was observed,
and NMNAT1 was added to the reaction mixture to install AMP
and form the respective NAD+ analogues. After reacting for
16 hours LCMS analysis revealed consumption of the mono-
nucleotides and formation of the NAD+-analogues, that where
purified using RP-HPLC to yield us compounds 1, 2 and 3 in
multi-milligram amounts (36, 26 and 25% yield, respectively) as
off-white powders.
Scheme 1. A) Synthesis of thionicotinamide riboside (5) a) AllOH, AcCl, 0 °C; b) PMBCl, NaH, DMF; c) KOtBu, DMF, 110 °C; d) THF, NaHCO3 (sat. aq.), I2; e) NaBH4,
MeOH; f) MsCl, Et3N, CH2Cl2; g) LiBr, MEK, 80 °C; h) Na2S, DMF, 100 °C; i) TFA, CH2Cl2; j) TBDPSCl, Im., CH2Cl2; k) Ac2O, pyr.; l) m-CPBA, CH2Cl2,   40 °C; m) Ac2O,
100 °C; n) nicotinamide, BSTFA, TMSOTf, ACN, 80 °C; o) HF/pyr.; p) NH3/MeOH, 0 °C. B) enzymatic conversion of ribosides 4–6 towards NAD
+ analogues 1–3.
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Next we investigated inhibition of SdeC activity by c-NAD+
(1), S-NAD+ (2) and BAD (3) using an ɛ-NAD+ hydrolysis
assay.[23] In ɛ-NAD+, the fluorescence of etheno-adenosine is
quenched by nicotinamide and the formation of ADPr  Ub as a
result of ART activity of SdeC releases nicotinamide, resulting in
a fluorescent signal. The increase in fluorescence is therefore a
direct measure of substrate ɛ-NAD+-consumption and enzyme
activity. In this assay, Ub and ɛ-NAD+ are incubated with SdeC
and increase in fluorescence is measured over time. We first
assessed the affinity of unmodified NAD+ by incubating SdeC
with both ɛ-NAD+ and NAD+. Such substrate competition
between the two NAD+ species led to a concentration-depend-
ent decrease in fluorescent signal upon increasing the amount
of NAD+, allowing us to determine the IC50 value of NAD
+ for
SdeC to be 27.7�1.9 μM (see extended data in Figure 3). When
performing a similar experiment where c-NAD+, S-NAD+ or BAD
were incubated at increasing concentrations with SdeC, Ub and
ɛ-NAD+, we observed concentration-dependent inhibition of
ART-activity for S-NAD+ and BAD. However, only a marginal
effect for c-NAD+ was detected in the used concentration range
up to 200 μM (Figure 3A). IC50 values for BAD and S-NAD
+ were
determined to be 27.9�6.5 and 38.9�3.9 μM, respectively
(Figure 3B). S-NAD+ thus is an inhibitor of SdeC with a
comparable affinity as native substrate NAD+, whereas BAD is a
good inhibitor with a slightly higher IC50.
Conclusion
In conclusion, we have shown the improved chemical synthesis
of thionicotinamide riboside and converted it alongside with
carbanicotinamide riboside and benzamide riboside to the
respective NAD+ analogues by using the enzyme combination
NRK1 and NMNAT1. The adaptability of this chemoenzymatic
approach, previously demonstrated only for S-NAD+, allowed
the fast and scalable (~5 mg) construction of all three NAD+
analogues, including c-NAD+ and BAD. Thus, we reveal that
minimal structural variation in the furanose ring as well as
modification of the nicotinamide part does not interfere with
the activity of the NRK1/NMNAT1 enzymes. We then tested the
three compounds on their inhibitory capacity towards patho-
genic Legionella enzyme SdeC. S-NAD+ and BAD, showed
micromolar inhibition of the Legionella enzyme, with an affinity
for the enzyme in the same order of magnitude as the native
substrate NAD+. The carba analogue only minimally inhibited
the ART activity of SdeC, indicating that the substitution of the
oxygen atom in the furanose ring with methylene was not
tolerated, probably due to its rigidity enhancing effect on the
five-membered ring. When comparing the IC50 values of S-
NAD+ (27.9 μM) and BAD (38.9 μM) with NAD+ (27.7 μM), the S-
NAD+ seems to be most comparable to the native substrate. To
the best of our knowledge these are the first NAD+-mimics that
inhibit a member of the Legionella SidE family. Although the
compounds tested here will most likely not be specific for the
Legionella SidE family, as they also inhibit other NAD+
-consuming enzymes, they do form a starting point for
obtaining selective inhibitors. A recent report shows that
relatively minor modifications at the 3’-OH of a modified NAD+
analogue greatly enhances selectivity towards specific
enzymes.[24] Based on the combined insight that both the
thioribofuranose and benzamide scaffold in NAD+ mimics
inhibits SdeC activity, and that 3’-OH modification can tune
specificity of ADPr transferases, potential selective inhibitors
Figure 3. A) ɛ-NAD+ hydrolysis assays showing nicotinamide displacement
by SdeC ART activity and its concentration-dependent inhibition by BAD, S-
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might be developed in the near future giving rise to a new class
of antibiotic candidates against Legionella infection.
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Modestly modified: Three stable
NAD+ analogues namely, c-NAD+, S-
NAD+ and BAD were prepared by
using an optimized chemoenzymatic
procedure and were compared side-
by-side for enzyme inhibition of Le-
gionella effector enzyme SdeC, which
is important in bacterial virulence.
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